Japan
Cellusion Inc. is a Tokyo-based startup in the biotechnology and healthcare industries, with a mission to regenerate human potential and bring more freedom and smiles to the world. Founded in 2015, the company's innovative approach has attracted significant attention and investments, including the latest ¥2.83B Series C investment on 07 June 2023. The funding round was led by a consortium of esteemed investors, including Nissay Capital, SMBC Venture Capital, Axil Capital, DBJ Capital, JIC Venture Growth Investments, SPARX Asset Management, The University of Tokyo Edge Capital, Gemseki Inc., AIS CAPITAL LIMITED, and Nikon-SBI Innovation Fund.
Cellusion’s commitment to leveraging biotechnology to enhance healthcare and improve quality of life positions it as a promising player in the global market. Its location at Nihonbashi-Kobuna, Chuo-ku, Tokyo, Japan places it within a hub of innovative and technological advancement. The deep expertise and diverse network of its investors not only validate the potential of the company but also provide it with a strong foundation for future growth and expansion.
With its visionary slogan, “Regenerating Human Potential. More Freedom and More Smiles to the World,” Cellusion Inc. embodies a forward-thinking approach that aims to bring positive change to the world. The recent Series C investment is a testament to the confidence that industry leaders and investors have in the company's potential to create significant impact and drive meaningful advancements in biotechnology and healthcare. Cellusion Inc. is poised to make substantial contributions to the industry and society at large, making it an exciting prospect for venture capitalists seeking to invest in transformative and socially impactful ventures.
